ATE207758T1 - Verwendung von igf-1 - Google Patents

Verwendung von igf-1

Info

Publication number
ATE207758T1
ATE207758T1 AT93910528T AT93910528T ATE207758T1 AT E207758 T1 ATE207758 T1 AT E207758T1 AT 93910528 T AT93910528 T AT 93910528T AT 93910528 T AT93910528 T AT 93910528T AT E207758 T1 ATE207758 T1 AT E207758T1
Authority
AT
Austria
Prior art keywords
pct
igf
treatment
medicament
sec
Prior art date
Application number
AT93910528T
Other languages
English (en)
Inventor
David B Dunger
Martin O Savage
Peter H Soenksen
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE207758T1 publication Critical patent/ATE207758T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT93910528T 1992-05-19 1993-05-14 Verwendung von igf-1 ATE207758T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9201573A SE9201573D0 (sv) 1992-05-19 1992-05-19 Use of igf-1
PCT/SE1993/000425 WO1993023071A1 (en) 1992-05-19 1993-05-14 Use of igf-1

Publications (1)

Publication Number Publication Date
ATE207758T1 true ATE207758T1 (de) 2001-11-15

Family

ID=20386281

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93910528T ATE207758T1 (de) 1992-05-19 1993-05-14 Verwendung von igf-1

Country Status (11)

Country Link
US (1) US5466670A (de)
EP (1) EP0613376B1 (de)
JP (1) JPH06509361A (de)
AT (1) ATE207758T1 (de)
AU (1) AU669894B2 (de)
CA (1) CA2112358A1 (de)
DE (1) DE69331045T2 (de)
NO (1) NO940180L (de)
NZ (1) NZ252359A (de)
SE (1) SE9201573D0 (de)
WO (1) WO1993023071A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US20020049422A1 (en) * 1994-03-31 2002-04-25 Brewitt Barbara A. Homeopathic preparations
US20060088575A1 (en) * 1994-03-31 2006-04-27 Brewitt Barbara A Homeopathic preparations of purified growth factors and purified growth hormones and associated carriers
SE9402370D0 (sv) * 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US5565428A (en) * 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
DE60016560T2 (de) 1999-01-06 2005-12-15 Genentech, Inc., South San Francisco Mutierte variante des insulin-ähnlichen wachstumsfaktor-i (igf-i)
DE60005806T2 (de) 1999-04-08 2004-08-05 Genentech, Inc., South San Francisco Zusammensetzung auf basis gegensätzlich geladener polypeptide
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
DK1282437T3 (da) 2000-05-16 2008-06-30 Genentech Inc Behandling af brusklidelser
US6984405B1 (en) 2000-12-15 2006-01-10 Naturalendo Tech Co., Ltd. Compositions for inducing secretion of insulin-like growth factor-1
NZ526672A (en) * 2001-02-09 2006-10-27 Genentech Inc Process for forming crystalline human insulin-like growth factor-1
AU2002248609B2 (en) 2001-03-14 2007-03-01 Genentech, Inc. IGF antagonist peptides
CN101022820A (zh) 2004-08-30 2007-08-22 特西卡股份有限公司 诊断和治疗胰岛素样生长因子缺陷疾病的方法和装置
EP2763692A2 (de) * 2011-10-06 2014-08-13 European Molecular Biology Laboratory Verwendung von igf-1 in der modulation der treg-zellaktivität sowie behandlung und vorbeugung von autoimmunen erkrankungen oder störungen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0123228B1 (de) * 1983-04-25 1993-09-29 Chiron Corporation Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren
US4963665A (en) * 1986-01-07 1990-10-16 Washington University Human preproinsulin-like growth factor I
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
GB8920381D0 (en) * 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes

Also Published As

Publication number Publication date
DE69331045D1 (de) 2001-12-06
JPH06509361A (ja) 1994-10-20
NO940180D0 (no) 1994-01-18
US5466670A (en) 1995-11-14
NZ252359A (en) 1997-05-26
NO940180L (no) 1994-01-18
EP0613376A1 (de) 1994-09-07
EP0613376B1 (de) 2001-10-31
AU669894B2 (en) 1996-06-27
WO1993023071A1 (en) 1993-11-25
SE9201573D0 (sv) 1992-05-19
AU4098893A (en) 1993-12-13
DE69331045T2 (de) 2002-03-21
CA2112358A1 (en) 1993-11-25

Similar Documents

Publication Publication Date Title
DE69331045D1 (de) Verwendung von igf-1
MX9701916A (es) Procedimiento para la investigacion de la interaccion de biomoleculas mediante resonancia de plasmones en la superficie.
DE3876052D1 (de) Medizinische verwendung.
UA27874C2 (uk) Препарат інсуліну людини, спосіб одержання препарату, спосіб лікування цукрового діабету
ATE170401T1 (de) Verfahren und zusammensetzungen zur behandlung von diabetes mellitus, hypoglykämie und anderer krankhafter zustände
ATE150316T1 (de) Verwendung von menschlichem igf-i
DE69412486D1 (de) Rekombinante viren und ihre verwendung bei der gentherapie
KR920700667A (ko) 세포간 점착분자 및 그의 결합리간드의 천식치료에의 이용
ATE138578T1 (de) Behandlung von insulinresistentem diabetes
CA2196174A1 (en) Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes
DE69123361D1 (de) Verwendung von interleukin-4 zur behandlung der festen tumoren
DE60012517D1 (de) Methoden zur behandlung von diabetes
ZA200107283B (en) Vascular adhesion molecules and modulation of their function.
ATE104855T1 (de) Verwendung von inositoltrisphosphat zur herstellung eines arzneimittels gegen knochenerkrakungen.
ATE228007T1 (de) Verwendung von wachstumshormone
ATE174629T1 (de) Herstellung von proteinen mittels protein 7b2
KR950703353A (ko) 인슐린-의존적 진성 당뇨병을 예방 또는 치료하기 위한 인터루킨-10의 용도(Use of IL-10 to prevent or treat insulin-dependent diabetes mellitus)
ATE157010T1 (de) Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen
PT914148E (pt) Tratamento do sindroma de insensibilidade parcial a hormona de crescimento
CA2116535A1 (en) A Method for Treatment of Patients with Chronic Liver Disease
DE69728654D1 (de) Verwendung von il-7 zur behandlung von autoimmunkrankheiten, insbesondere insulinabhängigem diabetes mellitus
ATE128867T1 (de) Verwendung von 3-aryl-5-alkylthio-4h-1,2,4- triazolen zur behandlung von überreflexen infolge von rückenmarkstrauma.
ES2046325T3 (es) Un equipo de ensayo para niveles de adipsina para uso en el diagnostico de anormalidades geneticas o metabolicas.
DE69218544D1 (de) Verwendung von BMY 14802 zur Behandlung von Angstzuständen bei Patienten mit Benzodiazepin-Entzugserscheinungen
ZA858672B (en) New use of 1,4-dihydropyridine derivatives and combinations thereof with calcitonins

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties